Tetraethylammonium bromide
Common Name: |
Tetraethylammonium bromide |
IUPAC Name: |
tetraethylazanium;bromide |
Molecular Formula: |
C8H20N+ |
SMILES: |
CC[N+](CC)(CC)CC.[Br-] |
Inchi: |
1S/C8H20N.BrH/c1-5-9(6-2,7-3)8-4;/h5-8H2,1-4H3;1H/q+1;/p-1 |
Inchi Key: |
HWCKGOZZJDHMNC-UHFFFAOYSA-M |
Cas No: |
71-91-0 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
1 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
2 |
Name |
Value |
Molecular Weight (g/mol) |
210.16 |
Mass (g/mol) |
209.078 |
Molar Refractivity |
51.87 |
Net Charge |
1 |
HBD |
|
HBA |
0 |
Rt Bonds |
4 |
Rings |
|
TPSA |
0.00 |
Hetero Atoms |
1 |
Heavy Atoms |
10 |
Aromatic Heavy Atoms |
0 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
|
Vapor Pressure (mmHg@25.00 °C) |
|
Vapor Density (Air =1) |
|
Fraction Csp3 |
1.00 |
LogP |
1.883 |
iLOGP |
-2.17 |
XLOGP3 |
-2.98 |
WLOGP |
-1.11 |
MLOGP |
-0.99 |
ESOL Log S |
1.00 |
ESOL Solubility (mg/ml) |
2090 |
ESOL Solubility (mol/l) |
9.96 |
ESOL Class: esol_class |
Highly soluble |
Ali Log S |
3.54 |
Ali Solubility (mg/ml) |
731000 |
Ali Solubility (mol/l) |
3480 |
Ali Class |
Highly soluble |
Silicos-IT LogSw |
-3.07 |
Silicos-IT Solubility (mg/ml) |
0.18 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
Low |
BBB Permeable |
0 |
PgP Substrate |
1 |
Log Kp (cm/s) |
-9.70 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
0 |
Plasm Protein Binding |
0.663 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
4.026 |
Carcinogenicity (Binary) |
1 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
1 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |